Health & Environmental Research Online (HERO)


Print Feedback Export to File
2851156 
Journal Article 
Integrated proteomic and miRNA transcriptional analysis reveals the hepatotoxicity mechanism of PFNA exposure in mice 
Wang, J; Yan, S; Zhang, W; Zhang, H; Dai, J 
2015 
Yes 
Journal of Proteome Research
ISSN: 1535-3893
EISSN: 1535-3907 
14 
330-341 
English 
Perfluoroalkyl chemicals (PFASs) are a class of highly stable man-made compounds, and their toxicological impacts are currently of worldwide concern. Administration of perfluorononanoic acid (PFNA), a perfluorocarboxylic acid (PFCA) with a nine carbon backbone, resulted in dose-dependent hepatomegaly in mice (0, 0.2, 1, and 5 mg/kg body weight, once a day for 14 days) and an increase in hepatic triglycerides (TG) and total cholesterol (TCHO) in the median dose group as well as serum transaminases in the high dose group. Using isobaric tags for relative and absolute quantitation (iTRAQ), we identified 108 (80 up-regulated, 28 down-regulated) and 342 hepatic proteins (179 up-regulated, 163 down-regulated) that exhibited statistically significant changes (at least a 1.2-fold alteration and P < 0.05) in the 1 and 5 mg/kg/d PFNA treatment groups, respectively. Sixty-six proteins (54 up-regulated, 12 down-regulated) significantly changed in both of the two treatment groups. Among these 54 up-regulated proteins, most were proteins related to the lipid metabolism process (31 proteins). The mRNA analysis results further suggested that PFNA exposure not only resulted in a fatty acid oxidation effect but also activated mouse liver genes involved in fatty acid and cholesterol synthesis. Additionally, three (2 down-regulated, 1 up-regulated) and 30 (14 down-regulated, 16 up-regulated) microRNAs (miRNAs) exhibited at least a 2-fold alteration (P < 0.05) in the 1 and 5 mg/kg/d PFNA treatment groups, respectively, Three miRNAs (up-regulated: miR-34a; down-regulated: miR-362-3p and miR-338-3p) significantly changed in both of the two treatment groups. The repression effect of miR-34a on fucosyltransferase 8 (Fut8) and lactate dehydrogenase (Ldha) was confirmed by luciferase activity assay and Western blot analysis. The results implied that PFNA exerted a hepatic effect, at least partially, by miRNAs mediated post-translational protein repression. 
PFNA; miRNAs; iTRAQ; hepatotoxicity 
• SR Automation
PFAS
• Additional PFAS (formerly XAgency)
     Literature Search November 2019
          Other Sources
               ATSDR
               TEDX
     Screened Studies
          Excluded
               Exclude (TIAB)
• Expanded PFAS SEM (formerly PFAS 430)
     Litsearch: September 2019
          Other Sources
               PFAS TOX Database
     Screened Studies
          Excluded
               Exclude (TIAB)
• ^Per- and Polyfluoroalkyl Substances (PFAS)
     PFOA (335-67-1) and PFOS (1763-23-1)
          Literature Search – Adverse outcome pathway (2015-present)
               WOS
     PFNA (375-95-1)
          Literature Search
               Pubmed
               WOS
• PFAS 150
     Literature Search Update December 2020
          WOS
     Literature Search August 2019
          PubMed
          Web of Science
          Other sources
               PFAS TOX Database
               ATSDR
     Screened Studies
          Excluded
               Exclude (TIAB)
     Perfluorinated compounds
     Perfluorononanoic acid
     Perfluorooctanoic acid
• PFNA
     Literature Search (August 2017)
          Pubmed
     Litsearch Update 2017-2018
          PFAS Untag
     Litsearch Addl Synonyms 2018
          Toxline
          WOS
     PFNA Literature Search pre-2019
          Pubmed
          WOS
     Literature Search
          Pubmed
          Toxline
          WOS
     Screening Results
          In vivo animal studies
               Liver tox
     PFNA HAWC Readout
          Animal
     Title and Abstract Screening
          Full Text Screening
               Studies Meeting PECO
                    Animal health effects studies
     June 2022 Pelch Database
     June 2022 PFAS150
• PFOA (335-67-1) and PFOS (1763-23-1)
     Literature Search – Adverse outcome pathway (2015-present)
          WOS
     Screening Results
          Excluded/Not on Topic
     Literature Search Update (2013-2019)
          WOS
• Yale PFAS Liver study